Live attenuated human rotavirus vaccine Porcine circovirus-free (GlaxoSmithKline Plc)

The objectives of this study were to evaluate the immunogenicity and safety of inactivated polio vaccine (IPV) when co-administered with a porcine circovirus (PCV)-free oral live attenuated human rotavirus (HRV) liquid vaccine from GlaxoSmithKline Biologicals (GSK) in healthy Chinese infants aged 6 to 10 weeks (enrollment age). - To demonstrate the immunological non-inferiority of IPV co-administered with Rotarix without PCV compared with IPV alone. - To assess the immunogenicity of IPV when co-administered with Rotarix without PCV and when administered alone. - To assess the immunogenicity of Rotarix without PCV when co-administered with IPV and when administered alone. - To assess the reactogenicity of Rotarix without PCV and IPV based on solicited systemic events. - To assess the safety of Rotarix without PCV based on unsolicited adverse events (AEs) and serious adverse events (SAEs), and the safety of IPV based on SAEs.